[Barrett's esophagus].

By J. Dolina, A. Hep, P. Dítě, H. Munzova, M. Kunovská, L. Husova, F. Vlckova, Z. Pilottova. Bratislava Medical Journal, 2000

1,282 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015, background): “Until we have a greater understanding of complex paracrine and noncell-autonomous interactions of cancer subclones, targeting a clonally dominant, truncal driver may provide a more effective drug development strategy than simply considering actionable alterations as present or absent (Lohr et al., 2”
Is there publication bias in the reporting of cancer risk in Barrett's esophagus? (2000, methodology): “The authors used the following criteria for inclusion in the study: (1) any journal article or text reporting a cancer risk expressible in cancers per patient-year of follow-up; (2) endoscopy with biopsy at baseline for any patient included in the cohort; (3) histologic confirmation of BE of all pat”